UA66339C2 - Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування - Google Patents

Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування Download PDF

Info

Publication number
UA66339C2
UA66339C2 UA98031545A UA98031545A UA66339C2 UA 66339 C2 UA66339 C2 UA 66339C2 UA 98031545 A UA98031545 A UA 98031545A UA 98031545 A UA98031545 A UA 98031545A UA 66339 C2 UA66339 C2 UA 66339C2
Authority
UA
Ukraine
Prior art keywords
truncated
protein
sequence
zeo
zome
Prior art date
Application number
UA98031545A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Шоу-Фен Ху
Original Assignee
Амген Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Інк. filed Critical Амген Інк.
Publication of UA66339C2 publication Critical patent/UA66339C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UA98031545A 1995-09-28 1996-09-16 Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування UA66339C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/535,681 US6184200B1 (en) 1995-09-28 1995-09-28 Truncated glial cell line-derived neurotrophic factor
PCT/US1996/014915 WO1997011964A1 (en) 1995-09-28 1996-09-16 Truncated glial cell line-derived neurotrophic factor

Publications (1)

Publication Number Publication Date
UA66339C2 true UA66339C2 (uk) 2004-05-17

Family

ID=24135310

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98031545A UA66339C2 (uk) 1995-09-28 1996-09-16 Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування

Country Status (24)

Country Link
US (5) US6184200B1 (ja)
EP (1) EP0920448B1 (ja)
JP (3) JP4153036B2 (ja)
KR (1) KR100334739B1 (ja)
CN (1) CN1283659C (ja)
AT (1) ATE314389T1 (ja)
AU (1) AU707528B2 (ja)
CA (1) CA2232749C (ja)
CZ (1) CZ297326B6 (ja)
DE (1) DE69635675T2 (ja)
DK (1) DK0920448T3 (ja)
EA (1) EA001204B1 (ja)
ES (1) ES2255713T3 (ja)
HU (1) HU226220B1 (ja)
IL (6) IL144018A0 (ja)
MX (1) MX9802278A (ja)
NO (1) NO322521B1 (ja)
NZ (1) NZ318697A (ja)
SI (1) SI0920448T1 (ja)
SK (1) SK288094B6 (ja)
TW (1) TW570926B (ja)
UA (1) UA66339C2 (ja)
WO (1) WO1997011964A1 (ja)
ZA (1) ZA968087B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6897061B1 (en) 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7245117B1 (en) 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
WO2008100966A1 (en) * 2007-02-12 2008-08-21 The Research Foundation Of State University Of New York Gdnf-derived peptides
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
US8446454B2 (en) * 2007-05-21 2013-05-21 Polycom, Inc. Dynamic adaption of a continuous presence videoconferencing layout based on video content
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
TW202325850A (zh) 2021-11-29 2023-07-01 大陸商上海瑞宏迪醫藥有限公司 Aadc、gdnf多核苷酸及其用於治療帕金森病

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
CA1332433C (en) 1989-09-29 1994-10-11 Robert L. Sutherland Ski structure and binding therefor
DK0423980T3 (da) 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
AU1443095A (en) 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
JP2010279360A (ja) 2010-12-16
HUP9802262A2 (hu) 1999-01-28
US20110251267A1 (en) 2011-10-13
HU226220B1 (hu) 2008-06-30
JPH11512709A (ja) 1999-11-02
DE69635675T2 (de) 2006-07-06
AU7074696A (en) 1997-04-17
ATE314389T1 (de) 2006-01-15
ES2255713T3 (es) 2006-07-01
IL144018A0 (en) 2002-04-21
AU707528B2 (en) 1999-07-15
SI0920448T1 (sl) 2006-04-30
IL144488A (en) 2006-12-31
SK288094B6 (sk) 2013-07-02
EP0920448A1 (en) 1999-06-09
DE69635675D1 (de) 2006-02-02
JP4909843B2 (ja) 2012-04-04
IL123761A (en) 2005-12-18
HK1021823A1 (en) 2000-07-07
MX9802278A (es) 1998-08-30
KR19990063825A (ko) 1999-07-26
US6184200B1 (en) 2001-02-06
CA2232749A1 (en) 1997-04-03
EP0920448B1 (en) 2005-12-28
JP2008067699A (ja) 2008-03-27
US20040214776A1 (en) 2004-10-28
EA199800301A1 (ru) 1998-10-29
US7611865B2 (en) 2009-11-03
JP4153036B2 (ja) 2008-09-17
NO981430L (no) 1998-03-30
SK38998A3 (en) 1999-07-12
EA001204B1 (ru) 2000-12-25
JP5241037B2 (ja) 2013-07-17
IL218336A0 (en) 2012-04-30
IL123761A0 (en) 1998-10-30
US7390781B2 (en) 2008-06-24
ZA968087B (en) 1997-06-12
US20040254114A1 (en) 2004-12-16
NZ318697A (en) 1999-09-29
US20040127419A1 (en) 2004-07-01
HUP9802262A3 (en) 2001-01-29
NO322521B1 (no) 2006-10-16
IL144018A (en) 2012-04-30
CA2232749C (en) 2003-03-25
CZ297326B6 (cs) 2006-11-15
WO1997011964A1 (en) 1997-04-03
CN1197461A (zh) 1998-10-28
DK0920448T3 (da) 2006-04-10
TW570926B (en) 2004-01-11
CN1283659C (zh) 2006-11-08
NO981430D0 (no) 1998-03-30
IL144488A0 (en) 2002-05-23
CZ88298A3 (cs) 1999-02-17
KR100334739B1 (ko) 2002-09-17

Similar Documents

Publication Publication Date Title
UA66339C2 (uk) Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування
EP0909316B1 (en) Glial cell line-derived neurotrophic factor receptor
UA73719C2 (en) Human interleukin-2 mutant which activates preferably t-cells as compared with natural killer cells, pharmaceutical composition, polynucleotide, vector, procariotic cell, a method for the stimulation of immune system
KR20050021502A (ko) 인터페론-β를 이용한 신부전증의 치료법
KR20180042432A (ko) 신규 인간 혈청 알부민 변이체
JP2002536018A (ja) グリコシル化レプチン組成物および関連する方法
CN110869386A (zh) 重组神经生长因子的组合物和方法
KR20050059195A (ko) 인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료
CA2291608C (en) Neurotrophic factor receptors
JP2001527402A (ja) Ｎｇｆ変異体
US7138251B1 (en) Polynucleotides encoding a neurotrophic factor receptor
WO2005058951A1 (ja) 糖鎖欠損型肝細胞増殖因子
WO1999003999A1 (en) Methods and compositions for inhibiting the proinflammatory response
KR100409099B1 (ko) 신경 손상 치료 기구
HK1021823B (en) Truncated glial cell line-derived neurotrophic factor